Akero Therapeutics ((AKRO)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Akero Therapeutics is conducting a Phase 3 study titled ‘A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis.’ The study aims to assess the safety and efficacy of Efruxifermin (EFX) in treating patients with NASH/MASH and fibrosis stages 2 or 3. This study is significant as it targets a condition with limited treatment options, potentially offering a new therapeutic avenue.
The intervention being tested is Efruxifermin, a drug administered via subcutaneous injection, designed to improve liver health in patients with NASH/MASH. The study includes two experimental groups receiving different doses of EFX (28 mg and 50 mg) and a placebo group for comparison.
The study design is interventional, with participants randomly assigned to parallel groups. It employs a quadruple masking approach, meaning that participants, care providers, investigators, and outcomes assessors are all blinded to the treatment allocations. The primary purpose of the study is treatment-focused.
The study began on December 1, 2023, with primary completion and estimated completion dates yet to be announced. The last update was submitted on July 29, 2025, indicating ongoing recruitment and progress.
Market implications of this study update could be significant for Akero Therapeutics, potentially boosting investor confidence and stock performance if results are favorable. The competitive landscape includes other companies developing treatments for NASH, making this study’s outcomes crucial for Akero’s market positioning.
The study is currently recruiting, with further details available on the ClinicalTrials portal.